• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Aug. 17 MSN Laboratories Ltd forayed into formulations segment by inaugurating its facility here on Friday.

The facility would enable production of around 400 million dosage forms and eight million liquid dosage forms.

The full production capacity would be achieved over next one year, according to Dr MSN Reddy, Chairman of MSN Group. The Group, which achieved Rs 30-crore turnover in the first quarter of the current fiscal year (Rs 140 crore in the pervious fiscal), invested Rs 10 crore in the plant.

“The formulations foray is a natural progression for us after making a strong foundation in bulk drug production. Initially we will cater to the domestic market needs and less regulated markets overseas,” Mr R. Srinivasan, General Manager (Finance), MSN Laboratories, told Business Line.

“We will be setting up a greenfield plant for regulated markets by the end of 2009,” he said. In the formulations segment, the company would focus in two/three therapeutic areas including cardiovascular and obesity, he added.

More Stories on : New Projects | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Fire at Alok Ind texturising plant

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line